Click here to navigate

  • ACOG
  • Clinical Perspectives
  • ROMA
  • Novel Approaches to Pelvic Mass Risk Assessment and Management: Case Reviews

    ACOG District II Annual Meeting - New York, October 18, 2019

    •  Full Video
    • Case Study Clips
    • FAQ Clips


  • Richard G. Moore, MD, FACS, FACOG

    • Professor University of Rochester
    • Chief, Division of Gynecologic Oncology University of Rochester Medical Center
    • Director, Targeted Therapeutics Laboratory Chair, Gynecology Service Line Wilmot Cancer Institute
  • Kevin Holcomb, MD, FACOG

    • Vice-Chairman of Gynecology
    • Director of Gynecologic Oncology
    • Director of Gynecologic Minimally Invasive Surgery
    • Weill Cornell Medicine
  • Clinical Perspectives

    Why consider other biomarkers in addition to CA125?
    Are multi-marker algorithms recommended for pelvic mass referrals to a gynecologic oncologist?
    When to refer patients with adnexal mass to a gynecologic oncologist?
    What improved performance does HE4 offer with CA125?
    Why a multi-marker algorithm was developed to assess a pelvic mass?
    What data support ROMA?
    How does ROMA compare to clinical assessment?
  • Full presentation and video

    ROMA slide thumbnails   Full video
    Download presentation slides   Watch full video recording